Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects
Neuromyelitis optica (NMO) is an immune-mediated demyelinative disorder of the central nervous system affecting mainly the optical nerves and the spinal cord. The recurrent course of the disease, with exacerbations and incomplete remissions, causes accumulating disability, which has a profound impac...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/6/2801 |
| _version_ | 1797541911972544512 |
|---|---|
| author | Marta Waliszewska-Prosół Justyna Chojdak-Łukasiewicz Sławomir Budrewicz Anna Pokryszko-Dragan |
| author_facet | Marta Waliszewska-Prosół Justyna Chojdak-Łukasiewicz Sławomir Budrewicz Anna Pokryszko-Dragan |
| author_sort | Marta Waliszewska-Prosół |
| collection | DOAJ |
| description | Neuromyelitis optica (NMO) is an immune-mediated demyelinative disorder of the central nervous system affecting mainly the optical nerves and the spinal cord. The recurrent course of the disease, with exacerbations and incomplete remissions, causes accumulating disability, which has a profound impact upon patients’ quality of life. The discovery of antibodies against aquaporin 4 (AQP4) and their leading role in NMO etiology and the formulation of diagnostic criteria have improved appropriate recognition of the disease. In recent years, there has been rapid progress in understanding the background of NMO, leading to an increasing range of treatment options. On the basis of a review of the relevant literature, the authors present currently available therapeutic strategies for NMO as well as ongoing research in this field, with reference to key points of immune-mediated processes involved in the background of the disease. |
| first_indexed | 2024-03-10T13:22:21Z |
| format | Article |
| id | doaj.art-7543c23be3f64160aa9a8d407e61e3ac |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T13:22:21Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7543c23be3f64160aa9a8d407e61e3ac2023-11-21T09:55:23ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01226280110.3390/ijms22062801Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future ProspectsMarta Waliszewska-Prosół0Justyna Chojdak-Łukasiewicz1Sławomir Budrewicz2Anna Pokryszko-Dragan3Department of Neurology, Wroclaw Medical University, 50-556 Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, 50-556 Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, 50-556 Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, 50-556 Wroclaw, PolandNeuromyelitis optica (NMO) is an immune-mediated demyelinative disorder of the central nervous system affecting mainly the optical nerves and the spinal cord. The recurrent course of the disease, with exacerbations and incomplete remissions, causes accumulating disability, which has a profound impact upon patients’ quality of life. The discovery of antibodies against aquaporin 4 (AQP4) and their leading role in NMO etiology and the formulation of diagnostic criteria have improved appropriate recognition of the disease. In recent years, there has been rapid progress in understanding the background of NMO, leading to an increasing range of treatment options. On the basis of a review of the relevant literature, the authors present currently available therapeutic strategies for NMO as well as ongoing research in this field, with reference to key points of immune-mediated processes involved in the background of the disease.https://www.mdpi.com/1422-0067/22/6/2801neuromyelitis optica spectrum disorderdemyelinating diseasesaquaporin 4autoimmune humoral responsetreatment |
| spellingShingle | Marta Waliszewska-Prosół Justyna Chojdak-Łukasiewicz Sławomir Budrewicz Anna Pokryszko-Dragan Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects International Journal of Molecular Sciences neuromyelitis optica spectrum disorder demyelinating diseases aquaporin 4 autoimmune humoral response treatment |
| title | Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects |
| title_full | Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects |
| title_fullStr | Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects |
| title_full_unstemmed | Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects |
| title_short | Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects |
| title_sort | neuromyelitis optica spectrum disorder treatment current and future prospects |
| topic | neuromyelitis optica spectrum disorder demyelinating diseases aquaporin 4 autoimmune humoral response treatment |
| url | https://www.mdpi.com/1422-0067/22/6/2801 |
| work_keys_str_mv | AT martawaliszewskaprosoł neuromyelitisopticaspectrumdisordertreatmentcurrentandfutureprospects AT justynachojdakłukasiewicz neuromyelitisopticaspectrumdisordertreatmentcurrentandfutureprospects AT sławomirbudrewicz neuromyelitisopticaspectrumdisordertreatmentcurrentandfutureprospects AT annapokryszkodragan neuromyelitisopticaspectrumdisordertreatmentcurrentandfutureprospects |